VectivBio Holding AG

Headquarters: Basel, Switzerland

CEO: Dr. Luca Santarelli M.D.


Market Cap

$474.9 Million

USD as of Jan. 1, 2023

Market Cap History

VectivBio Holding AG market capitalization over time

Evolution of VectivBio Holding AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of VectivBio Holding AG

Detailed Description

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Top 1-year algo backtest: +207.50%

$10,000 in July 2023 would now be $30,750 by following this algorithm daily at market close.

Boost your returns with Disfold DeepFinance... Now!

Try Disfold DeepFinance FREE

Stocks & Indices

VectivBio Holding AG has the following listings and related stock indices.

Stock: NASDAQ: VECT wb_incandescent



Aeschenvorstadt 36

Basel, 4051


Phone: 41 61 551 30 3